Literature DB >> 16755569

Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Gregory J Kato1, Matthew Hsieh, Roberto Machado, James Taylor, Jane Little, John A Butman, Tanya Lehky, John Tisdale, Mark T Gladwin.   

Abstract

In patients with sickle cell disease, anemia is a recognized risk factor for stroke, death, and the development of pulmonary hypertension. We have proposed that hemolytic anemia results in endothelial dysfunction and vascular instability and can ultimately lead to a proliferative vasculopathy leading to pulmonary hypertension. Consistent with this mechanism of disease, we now report a case series of six patients with obliterative central nervous system vasculopathy who also have pulmonary hypertension and high hemolytic rate. These patients, identified in the course of a prospective screening study for pulmonary hypertension, presented with neurological symptoms prompting neuroimaging studies. Compared to 164 other patients of similar age in the screened population, those with newly diagnosed or clinically active cerebrovascular disease have significantly lower hemoglobin levels and higher levels of lactate dehydrogenase. A review of the literature suggests that many clinical, epidemiological, and physiological features of the arteriopathy of pulmonary hypertension closely overlap with those of stroke in sickle cell disease, both known to involve proliferative vascular intimal and smooth muscle hypertrophy and thrombosis. These cases suggest that cerebrovascular disease and pulmonary hypertension in sickle cell disease share common mechanisms, in particular, reduced nitric oxide bioactivity associated with particularly high-grade hemolysis. Clinicians should suspect occult cerebrovascular disease in sickle cell patients with pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16755569      PMCID: PMC2206539          DOI: 10.1002/ajh.20642

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  43 in total

1.  Prediction of adverse outcomes in children with sickle cell disease.

Authors:  S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

Review 2.  Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations.

Authors:  K Ohene-Frempong
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

3.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 4.  Hemolytic anemia-associated pulmonary hypertension in sickle cell disease.

Authors:  Elaina E Lin; Griffin P Rodgers; Mark T Gladwin
Journal:  Curr Hematol Rep       Date:  2005-03

5.  Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition.

Authors:  J A French; D Kenny; J P Scott; R G Hoffmann; J D Wood; A G Hudetz; C A Hillery
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

6.  Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury.

Authors:  Karl A Nath; Joseph P Grande; Anthony J Croatt; Elena Frank; Noel M Caplice; Robert P Hebbel; Zvonimir S Katusic
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

7.  Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.

Authors:  C R Morris; F A Kuypers; S Larkin; E P Vichinsky; L A Styles
Journal:  J Pediatr Hematol Oncol       Date:  2000 Nov-Dec       Impact factor: 1.289

8.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

9.  Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease.

Authors:  K A Nath; V Shah; J J Haggard; A J Croatt; L A Smith; R P Hebbel; Z S Katusic
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-12       Impact factor: 3.619

10.  Hemolysis-associated priapism in sickle cell disease.

Authors:  Vikki G Nolan; Diego F Wyszynski; Lindsay A Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

View more
  35 in total

1.  Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia.

Authors:  Philip E Thuma; Janneke van Dijk; Rick Bucala; Zufan Debebe; Sergei Nekhai; Thea Kuddo; Mehdi Nouraie; Günter Weiss; Victor R Gordeuk
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

Review 2.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

3.  Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

4.  Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years.

Authors:  Margaret T Lee; Tania Small; Muhammad A Khan; Erika B Rosenzweig; Robyn J Barst; Gary M Brittenham
Journal:  Br J Haematol       Date:  2009-06-25       Impact factor: 6.998

5.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

6.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2016-10

Review 7.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

8.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

Review 9.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

10.  Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin.

Authors:  Sergei Nekhai; Min Xu; Altreisha Foster; Ishmael Kasvosve; Sharmin Diaz; Roberto F Machado; Oswaldo L Castro; Gregory J Kato; James G Taylor; Victor R Gordeuk
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.